<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00693056</url>
  </required_header>
  <id_info>
    <org_study_id>RX-10100-P2A-001</org_study_id>
    <nct_id>NCT00693056</nct_id>
  </id_info>
  <brief_title>Efficacy Study of RX-10100 to Treat Erectile Dysfunction (ED)</brief_title>
  <official_title>A Double-Blinded, Randomized, Placebo-Controlled, Dose-Exploring Study of RX-10100 for Eight Weeks of On-Demand Administration in Subjects With Erectile Dysfunction (ED)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rexahn Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rexahn Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this Phase IIa trial is to determine the effective doses and&#xD;
      treatment period for an upcoming RX-10100 Phase IIb trial in subjects with erectile&#xD;
      dysfunction (ED). The secondary objectives of this trial are to evaluate the safety and the&#xD;
      quality of life in subjects with ED receiving RX-10100 treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Scores on IIEF-EF Questionnaires and on SEP Questions II and III</measure>
    <time_frame>Weeks 4 and 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scores on other domains of IIEF, other questions on Subject Diaries, RigiScan measurement, and ED-QoL questionnaires</measure>
    <time_frame>Weeks 4 and 8</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Erectile Dysfunction (ED)</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (w/o API)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RX-10100 5mg</intervention_name>
    <description>5 mg/dose of RX-10100</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Zoraxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RX-10100 10mg</intervention_name>
    <description>10 mg/dose of RX-10100</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Zoraxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RX-10100 15mg</intervention_name>
    <description>15 mg/dose of RX-10100</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Zoraxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have had ED for at least six months&#xD;
&#xD;
          -  Stable, heterosexual relationship for at least 3 months&#xD;
&#xD;
          -  Make at least one attempt of sexual intercourse per week during the untreated, 2-week&#xD;
             screening period&#xD;
&#xD;
          -  At least 50% of attempts of sexual intercourse during the untreated baseline period&#xD;
             must be unsuccessful&#xD;
&#xD;
          -  'Moderate' or 'mild to moderate' ED, defined as an IIEF-EF domain score between 11 and&#xD;
             21 measured&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Following previous or current medical conditions&#xD;
&#xD;
               -  Any unstable medical, psychiatric, or substance abuse disorder&#xD;
&#xD;
               -  Penile anatomical abnormalities&#xD;
&#xD;
               -  Primary hypoactive sexual desire&#xD;
&#xD;
               -  Spinal cord injury&#xD;
&#xD;
               -  Hypogonadism&#xD;
&#xD;
               -  Surgical prostatectomy&#xD;
&#xD;
               -  Stable or unstable angina pectoris&#xD;
&#xD;
               -  Myocardial infarction, stroke, or life-threatening arrhythmia&#xD;
&#xD;
               -  Uncontrolled atrial fibrillation/flutter at screening&#xD;
&#xD;
               -  Severe chronic or acute liver disease&#xD;
&#xD;
               -  Moderate or severe hepatic impairment&#xD;
&#xD;
               -  Clinically significant chronic hematological disease&#xD;
&#xD;
               -  Bleeding disorder&#xD;
&#xD;
               -  Significant active peptic ulcer disease&#xD;
&#xD;
               -  Resting hypotension or hypertension&#xD;
&#xD;
               -  Malignancy (cancers)&#xD;
&#xD;
               -  NYHA Class II to IV heart failures&#xD;
&#xD;
               -  Positive test for Hepatitis B surface antigen (HBsAg) or Hepatitis C&#xD;
&#xD;
               -  Symptomatic postural hypotension&#xD;
&#xD;
          -  Following concomitant medication&#xD;
&#xD;
               -  Androgens or estrogens&#xD;
&#xD;
               -  Anti-androgens&#xD;
&#xD;
               -  Potent inhibitors of cytochrome P450 3A4&#xD;
&#xD;
               -  Any other investigational drug within 30 days before Visit 1&#xD;
&#xD;
               -  Any treatment for ED within 7 days before Visit 1 or during the study&#xD;
&#xD;
               -  Antibiotics in the penicillin class&#xD;
&#xD;
          -  Following abnormal laboratory values&#xD;
&#xD;
               -  Serum total testosterone level (at least 25% lower)&#xD;
&#xD;
               -  Serum creatinine (&gt; 3.0 mg/dl)&#xD;
&#xD;
               -  Elevation of AST and/or ALT (&gt; 3 times the upper limit of normal)&#xD;
&#xD;
               -  Diabetic subjects with an HbAlc (&gt; 6.5%)&#xD;
&#xD;
          -  Subjects with known hypersensitivity to amoxicillin&#xD;
&#xD;
          -  Subjects with a history of unresponsiveness to any PDE5 Inhibitor treatment or a&#xD;
             history of significant side effects leading to its treatment discontinuation&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyungjoo Hugh Lee, MS</last_name>
    <role>Study Director</role>
    <affiliation>Rexahn Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Greenbelt</city>
        <state>Maryland</state>
        <zip>20770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westampton</city>
        <state>New Jersey</state>
        <zip>08060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <study_first_submitted>June 4, 2008</study_first_submitted>
  <study_first_submitted_qc>June 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2008</study_first_posted>
  <last_update_submitted>May 4, 2009</last_update_submitted>
  <last_update_submitted_qc>May 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2009</last_update_posted>
  <responsible_party>
    <name_title>Hyungjoo Lee / Associate Director, Product Development Management</name_title>
    <organization>Rexahn Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>Erectile Dysfunctions</keyword>
  <keyword>ED</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>beta-Lactams</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

